The identification of presymptomatic parkinsonism: Clinical and {18F}dopa positron emission tomography studies in an irish kindred
Corresponding Author
Dr. G. V. Sawle DM
Clinical Sciences Section, Medical Research Council Cyclotron Unit, Hammersmith Hospital, London, England
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, England
MRC Cyclotron Unit, Hammersmith Hospital, 150 DuCane Road, London W12 0HS, EnglandSearch for more papers by this authorS. J. Wroe MRCP
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, England
Search for more papers by this authorA. J. Lees MD
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, England
Search for more papers by this authorD. J. Brooks MD
Clinical Sciences Section, Medical Research Council Cyclotron Unit, Hammersmith Hospital, London, England
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, England
Search for more papers by this authorR. S. J. Frackowiak MD
Clinical Sciences Section, Medical Research Council Cyclotron Unit, Hammersmith Hospital, London, England
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, England
Search for more papers by this authorCorresponding Author
Dr. G. V. Sawle DM
Clinical Sciences Section, Medical Research Council Cyclotron Unit, Hammersmith Hospital, London, England
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, England
MRC Cyclotron Unit, Hammersmith Hospital, 150 DuCane Road, London W12 0HS, EnglandSearch for more papers by this authorS. J. Wroe MRCP
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, England
Search for more papers by this authorA. J. Lees MD
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, England
Search for more papers by this authorD. J. Brooks MD
Clinical Sciences Section, Medical Research Council Cyclotron Unit, Hammersmith Hospital, London, England
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, England
Search for more papers by this authorR. S. J. Frackowiak MD
Clinical Sciences Section, Medical Research Council Cyclotron Unit, Hammersmith Hospital, London, England
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, England
Search for more papers by this authorAbstract
An Irish kindred is described in which 5 of 10 siblings in the fourth or fifth decade of life developed an akinetic-rigid syndrome clinically indistinguishable from idiopathic Lewy body Parkinson's disease. Four of these patients were scanned by positron emission tomography (PET) with {18F}dopa after clinical diagnosis and in all, a profound impairment of tracer uptake into the striatum was recorded. The fifth patient was initially scanned at a time when he was asymptomatic and normal by clinical examination. His scan showed impaired tracer uptake, indicating a subclinical defect in the presynaptic nigrostriatal system. Within months of his scan, he too developed subtle symptoms and signs of parkinsonism although there was little further clinical piogression or change in his PET scan over the following year. A clinically normal sibling was also scanned and found to have subclinical impairment of [18F}dopa uptake in the putamen. The 19-year-old daughter of an affected sibling had a mild postural tremor but no other symptoms or signs. The {18F}dopa uptake in her putamen fell at the borderline between normal and parkinsonian values. This study confirms that PET can identify preclinical parkinsonism in at-risk subjects. The finding of abnormalities in several clinically unaffected family members suggests that family studies based on clinical assessment alone may miss a significant number of subclinically affected individuals, leading to an underestimate of any genetic component to Parkinson's disease.
References
- 1 Spinks TJ, Jones T, Gilardi MC, Heather JD. Physical performance of the latest generation of commercial positron scanner. IEEE Trans Nucl Med 1988; 35: 721–725
- 2 Talairach J, Tournoux, P. Coplanar stereotaxic atlas of the human brain. New York: Georg Thieme, 1988
- 3 Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584–590
- 4 Tedroff J, Aquilonius S-M, Laihinen A, et al. Striatal kinetics of [11C]-( + )-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neural Scand 1990; 81: 24–30
- 5 Sawle GV, Colebatch JG, Shah A, et al. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990; 28: 799–804
- 6 Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427–442
- 7 Godfrey, K. Statistics in practice. Comparing the means of several groups N Engl J Med 1985; 23: 1450–1456
- 8 Mazziotta JC. The continuing challenge of primary brain tumor management: the contribution of positron emission tomography. Ann Neurol 1991; 29: 345–346
- 9 Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983; 3O5: 137–138
- 10 Diffley DM, Costa JL, Sokoloski EA, et al. Direct observation of 6-fluorodopamine in guinea pig nerve microsacs by 19F NMR. Biochem Biophys Res Commun 1983; 110: 740–745
- 11 Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986; 49: 853–860
- 12 Brooks DJ, Ibañez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990, 28: 547–555
- 13 Sawle GV, Brooks DJ, Marsden CD, Frackowiak RSJ. Corticobasal degeneration: a unique pattern of regional cortical oxygen metabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 1991; 114: 541–556
- 14 Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 318: 876–880
- 15 Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990; 47: 1290–1298
- 16 Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991; 54: 388–396
- 17 Bhatt MH, Snow BJ, Martin WRW, et al. Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol 1991; 29: 673–677
- 18 Sawle GV. The rate of progression of Parkinson's disease. Ann Neurol 1992; 31: 229
- 19 Sawle GV, Bloomfield PM, Björklund A, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: positron emission tomography [18F]-6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol 1992; 31: 166–173
- 20 Pate BD, Snow BJ, Hewitt KA, et al. The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates. J Nucl Med 1991; 32: 1246–1251
- 21 Guttman M, Yong VW, Kin SU, et al. Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys. Synapse 1988; 2: 469–473
- 22 Calne DB, Langston JW, Martin WRW, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985; 317: 246–248
- 23 Snow BJ, Peppard RF, Guttman M, et al. Positron emission tomogcaphic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. Arch Neurol 1990; 47: 870–874
- 24 Brooks DJ. Detection of preclinical Parkinson's disease with PET. Neurology 1991; 41 (suppl 2): 24–27
- 25 Sawle GV, Bench CJ, Cunningham VJ, et al. The identification of pre-clinical Parkinson's disease: discriminant function analysis of PET 6-L-18F-fluorodopa data. J Cereb Blood Flow Metab 1991; 11 (suppl 2): S811
- 26 Mjones H. Paralysis agitans: a clinical and genetic study. Acta Psychiatr Neurol Scand Suppl 1949; 54: 18–194
- 27 Duvoisin RC. The cause of Parkinson's disease. In: CD Marsden, S Fahn, eds. Movement disorders. London: Butterworths, 1982: 8–24
- 28 Ward CD, Duvoisin RC, Ince SE, et al. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983: 33: 815–824
- 29 Duvoisin RC, Eldridge R, Williams AC, et al. Twin study of Parkinson's disease. Neurology 1981; 31: 77–80
- 30 Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neuro surg Psychiatry 1983, 51: 745–752
- 31 Burn DJ, Plavford ED, Mark MH, et al. Parkinson's disease in twins studied with 18F-dopa and PET. J Cereb Blood Flow Metab 1991; 11 (suppl 2): S228
- 32 Duvoisin RC. Is Parkinson's disease acquired or inherited? Can J Neurol Sci 1984; 11: 151–155
- 33 Spellman GG. Report of familial cases of parkinsonism. JAMA 1962; 179: 372–374
- 34 Perry TL, Bratty PJA, Hansen S, Kennedy J. Hereditary mental depression and parkinsonism with taurine deficiency. Arch Neurol 1975; 32: 108–113
- 35 Purdy A, Hahn A, Barnett HJM, et al. Familial fatal parkinsonism with alveolar hypoventilation and mental depression. Ann Neurol 1979: 6: 523–531
- 36 Golbe LI, Di Iorio G, Bonavita V, et al. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990; 27: 276–282
- 37 Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283–2301